|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||176.50 - 176.50|
|52 Week Range||111.95 - 190.25|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||27.79|
|Forward Dividend & Yield||1.69 (0.92%)|
|Ex-Dividend Date||Apr 26, 2021|
|1y Target Est||N/A|
Will the timely new product position Merck KGaA as an upstream supplier for the entire mRNA medicine world and allow it to reap the benefits, or is it unlikely to reward shareholders? To start, let's quickly review the scientific concepts at hand so that it's clear why Merck KGaA's new product is worth knowing about. As you may know, lipid molecules don't dissolve in water.
MKKGY earnings call for the period ending March 31, 2021.
Merck KGaA on Wednesday said that U.S. regulations that give priority to U.S. government contracts to purchase COVID-19 vaccines are a challenge as it seeks to meet soaring demand for its lab equipment and supplies across the globe. She said U.S. law required that a preference be given to so-called rated state orders for COVID-19 programmes over any other orders. "For us, all our customers and all the other COVID-19 programmes are very crucial and we are making capacity expansion a top priority of our agenda," she said, pointing to investment projects both in the United States and Europe.